Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis

Company Overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Key Stats

• Today's Range: $61.00 to $61.00
• 50-Day Range: $50.14 to $70.08
• 52-Week Range: $49.98 to $136.76
• Volume: N/A
• Average Volume: 497 shs
• Market Capitalization: $4.33 billion
• P/E Ratio: 4.28
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

ZLDPF Stock Analysis - Frequently Asked Questions

How have ZLDPF shares performed this year?

Zealand Pharma A/S's stock was trading at $102.36 at the start of the year. Since then, ZLDPF stock has decreased by 40.4% and is now trading at $61.00.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (OTCMKTS:ZLDPF) released its quarterly earnings data on Thursday, August, 14th. The company reported $16.06 earnings per share for the quarter, missing the consensus estimate of $16.72 by $0.66. The firm earned $1.43 billion during the quarter, compared to analyst estimates of $9.18 billion. Zealand Pharma A/S had a net margin of 73.90% and a trailing twelve-month return on equity of 82.30%.

How do I buy shares of Zealand Pharma A/S?

Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/21/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ZLDPF
• Previous Symbol: NASDAQ:ZLDPF
• CIK: 2068427
• Web: www.zealandpharma.com
• Phone: 45-8877-3600
• Fax: 45-8877-3898
• Employees: 340
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): $14.24
• Trailing P/E Ratio: 4.28
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$156.43 million
• Net Margins: 73.90%
• Pretax Margin: -2,136.10%
• Return on Equity: 82.30%
• Return on Assets: 75.17%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 25.10
• Quick Ratio: 25.07

Sales & Book Value

• Annual Sales: $9.09 million
• Price / Sales: 476.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.59 per share
• Price / Book: 3.47

Miscellaneous

• Outstanding Shares: 71,020,000
• Free Float: N/A
• Market Cap: $4.33 billion
• Optionable: Not Optionable
• Beta: 0.71